Update shared on16 Aug 2025
Fair value Increased 5.65%Shilpa Medicare's consensus price target has increased to ₹1028, driven primarily by a notable rise in its future P/E multiple despite a slight decline in net profit margin.
What's in the News
- Secured world's first CDSCO approval for NorUDCA Tablets 500mg, the first therapy targeting NAFLD; plans rapid commercialization in India and pursuit of global regulatory pathways.
- Announced board meeting to consider Q1 FY26 results, AGM date, re-appointment of Chairman and Whole-Time Director, proposal for bonus shares, and other matters.
- Led a strategic financing round in Alveolus Bio; Shilpa Biologics to serve as exclusive global development and manufacturing partner for Alveolus Bio's resMIT platform, advancing assets for respiratory diseases.
- Lost a patent infringement lawsuit regarding generic Lenvima in a U.S. court; cannot market the product in the U.S. until patent expiry in February 2036, but may appeal the decision.
- Scheduled board meeting to consider audited FY25 results and dividend recommendation.
Valuation Changes
Summary of Valuation Changes for Shilpa Medicare
- The Consensus Analyst Price Target has risen from ₹973.50 to ₹1028.
- The Future P/E for Shilpa Medicare has significantly risen from 20.03x to 24.28x.
- The Net Profit Margin for Shilpa Medicare has fallen from 26.63% to 24.95%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.